Single-inhaler triple therapy is associated with a favorable benefit-risk profile compared with dual therapy for patients with symptomatic COPD and a history of exacerbations.
Both dual bronchodilation and triple therapy demonstrated similar rates of mortality in patients with moderate to severe COPD at low risk for exacerbations.
Twice daily gefapixant 45 mg was associated with a clinically meaningful reduction in cough frequency in patients with chronic cough.
Early identification if interstitial lung disease (ILD), followed by subsequent tocilizumab therapy initiation, may preserve lung function in patients with systemic sclerosis-associated ILD.
The novel ORACLE scale (Oxford Asthma Attack Risk Scale) demonstrated potential to predict — and subsequently prevent — asthma attacks using biomarkers of type 2 airway inflammation.
Patients with normal adrenal function are largely able to eliminate the use of oral corticosteroids or achieve a daily dose of 5 mg or less.
Study shows reductions in intraocular pressures and antiglaucoma medication use.
Investigators assessed the efficacy and tolerability of a high-concentration capsaicin 8% patch to treat diabetic peripheral nerve pain, either alone or in combination with standard oral therapies.
